InsiderClue
← All stocks

Labcorp

LH Net selling
CIK 0000920148 #284 in the set updated 17 Sep 2026
Bought (120 mo)
$1.04M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$175.44M
$18.90M on a plan · $105.33M straight out of an exercise
Sold at will
$51.21M
114 of 210 sales
Net
−$174.40M
−$50.17M against sales at will

By person

36 insiders · 219 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
KING DAVID P
Director
—
$63.14M (15) scheduled
−$63.14M
344,155
0.4244%
$109.45M
+77.8%
EISENBERG GLENN A
Executive Vice President
—
$34.20M (27) scheduled
−$34.20M
37,920
0.0468%
$12.06M
+358.6%
Schechter Adam H
President & CEO
—
$14.69M (10) scheduled
−$14.69M
102,565
0.1265%
$32.62M
+2,192%
van der Vaart Sandra D
EVP, Corporate Affairs
—
$8.53M (33) scheduled
−$8.53M
6,239
0.0077%
$1.98M
+368.6%
ANDERSON KERRII B
Director
—
$7.56M (19) scheduled
−$7.56M
6,563
0.0081%
$2.09M
−62.5%
Schroeder Mark S
EVP, Pres Diagnostics & COO
—
$7.42M (22) scheduled
−$7.42M
12,677
0.0156%
$4.03M
+1,951%
BELINGARD JEAN-LUC
Director
—
$6.41M (4) scheduled
−$6.41M
17,781
0.0219%
$5.65M
−41.8%
BERBERIAN LANCE
EVP, Special Advisor, Strategy
—
$5.28M (6)
−$5.28M
18,652
0.0230%
$5.93M
+1,436%
EBERTS F SAMUEL III
Chief Legal Officer, Secretary
—
$4.89M (1) scheduled
−$4.89M
28,823
0.0355%
$9.17M
+59.5%
Kirchgraber Paul R
CEO, Covance Drug Development
—
$3.95M (4) scheduled
−$3.95M
12,946
0.0160%
$4.12M
+193.8%
Wilkinson Peter J
SVP, Chief Accounting Officer
—
$3.73M (15) scheduled
−$3.73M
1,770
0.0022%
$562.97K
+1,270%
Dodson Edward T
Principal Accounting Officer
—
$2.84M (3) scheduled
−$2.84M
13,663
0.0168%
$4.35M
+311.3%
Uthgenannt Lisa J
Chief Human Resources Officer
—
$2.69M (4)
−$2.69M
4,660
0.0057%
$1.48M
+23.3%
Summy Amy B.
EVP, Chief Marketing Officer
—
$2.27M (7) scheduled
−$2.27M
6,956
0.0086%
$2.21M
—
Parham Richelle P
Director
—
$1.78M (1)
−$1.78M
3,366
0.0042%
$1.07M
—
Williams R Sanders
Director
—
$1.47M (11)
−$1.47M
8,120
0.0100%
$2.58M
+50.0%
MITTELSTAEDT ROBERT E JR
Director
—
$1.37M (6) scheduled
−$1.37M
15,515
0.0191%
$4.93M
+36.7%
Gilliland Dwight Gary
Director
—
$1.30M (11)
−$1.30M
6,656
0.0082%
$2.12M
+128.6%
NEUPERT PETER M
Director
$922.82K (3)
—
+$922.82K
13,784
0.0170%
$4.38M
—
Caveney Brian J
EVP, Pres of BLS, CMO & CSO
$20.42K (2)
$923.46K (2)
−$903.03K
36,492
0.0450%
$11.61M
+3,767%
Meltzer Jonathan C
EVP, COO
—
$298.76K (4) scheduled
−$298.76K
3,620
0.0045%
$1.15M
+43.8%
Gary M. Huff
CEO, LabCorp Diagnostics
—
$293.82K (1)
−$293.82K
1,850
0.0023%
$588.21K
+359.4%
Kyle Kathryn W
EVP, Chief Legal Officer
—
$227.41K (2) scheduled
−$227.41K
3,904
0.0048%
$1.24M
+27.9%
DiVincenzo Jonathan P.
EVP, Pres, Central Labs & Intl
—
$107.75K (1)
−$107.75K
5,461
0.0067%
$1.74M
+65.0%
Seltz Judith C
EVP, CHRO
$99.36K (2)
—
+$99.36K
4,182
0.0052%
$1.33M
+1,075%
Vaughn Bryan T
EVP and President, Diagnostics
—
$66.97K (1) scheduled
−$66.97K
6,746
0.0083%
$2.15M
+31.1%
Ratliff John D
CEO, Covance Drug Development
—
—
—
16,941
0.0209%
$5.39M
—
Kong Garheng
Director
—
—
—
13,739
0.0169%
$4.37M
+308.4%
Davis Jeffrey A.
Director
—
—
—
5,460
0.0067%
$1.74M
—
GRAHAM ANITA Z
EVP, CHRO
—
—
—
5,185
0.0064%
$1.65M
+17,183%
Oyegunwa Akinbolade
EVP, CIO & CTO
—
—
—
5,064
0.0062%
$1.61M
+89.9%
Bailey Megan D.
EVP, Pres, Central Labs & Intl
—
—
—
4,851
0.0060%
$1.54M
+3,876%
Wengel Kathryn E
Director
—
—
—
4,133
0.0051%
$1.31M
—
Kliphouse Kirsten Marie
Director
—
—
—
3,160
0.0039%
$1.00M
—
Rothman Paul
Director
—
—
—
2,571
0.0032%
$817.63K
+19,677%
Wang Julia Aijun
Chief Financial Officer, EVP
—
—
—
1,817
0.0022%
$577.92K
+29,027%

Individual transactions

61
Insider
Date
Role
Action
Shares
Price
Amount
Wilkinson Peter J
3 Aug 2026
SVP, Chief Accounting Officer
Sold after exercise
1,338
$309.23
$413.75K
Wilkinson Peter J
3 Aug 2026
SVP, Chief Accounting Officer
Sold after exercise
82
$309.22
$25.36K
Schechter Adam H
11 Feb 2026
President & CEO
Sold after exercise
5,273
$284.38
$1.50M
van der Vaart Sandra D
13 Aug 2025
EVP, Chief Legal Officer
Sold after exercise
3,903
$271.42
$1.06M
Schroeder Mark S
28 Feb 2025
EVP, Pres Diagnostics & COO
Sold after exercise
5,339
$249.23
$1.33M
Wilkinson Peter J
18 Feb 2025
SVP, Chief Accounting Officer
Sold after exercise
1,413
$246.10
$347.74K
Schechter Adam H
11 Feb 2025
President & CEO
Sold after exercise
6,121
$244.62
$1.50M
EISENBERG GLENN A
2 Dec 2024
Executive Vice President
Sold after exercise
11,711
$240.43
$2.82M
Summy Amy B.
22 Nov 2024
EVP, Chief Marketing Officer
Sold after exercise
3,672
$238.91
$877.14K
Schroeder Mark S
7 Mar 2024
EVP, Pres Diagnostics & COO
Sold after exercise
5,048
$218.45
$1.10M
EISENBERG GLENN A
21 Feb 2024
Chief Financial Officer, EVP
Sold after exercise
1,553
$217.98
$338.53K
EISENBERG GLENN A
21 Feb 2024
Chief Financial Officer, EVP
Sold after exercise
6,665
$217.52
$1.45M
EISENBERG GLENN A
21 Feb 2024
Chief Financial Officer, EVP
Sold after exercise
7,907
$215.68
$1.71M
EISENBERG GLENN A
21 Feb 2024
Chief Financial Officer, EVP
Sold after exercise
18,379
$215.37
$3.96M
Kirchgraber Paul R
19 May 2023
CEO, Covance Drug Development
Sold after exercise
4,300
$216.91
$932.71K
Schroeder Mark S
18 May 2023
EVP, Pres Diagnostics & COO
Sold after exercise
1,500
$216.77
$325.16K
Kirchgraber Paul R
21 Feb 2023
CEO, Covance Drug Development
Sold after exercise
8,000
$250.58
$2.00M
EISENBERG GLENN A
3 Aug 2022
Chief Financial Officer, EVP
Sold after exercise
1,500
$254.88
$382.32K
EISENBERG GLENN A
3 Aug 2022
Chief Financial Officer, EVP
Sold after exercise
19,338
$254.26
$4.92M
EISENBERG GLENN A
3 Aug 2022
Chief Financial Officer, EVP
Sold after exercise
11,262
$253.27
$2.85M
Wilkinson Peter J
1 Aug 2022
SVP, Chief Accounting Officer
Sold after exercise
10
$258.71
$2.59K
Wilkinson Peter J
1 Aug 2022
SVP, Chief Accounting Officer
Sold after exercise
757
$258.60
$195.76K
Wilkinson Peter J
1 Aug 2022
SVP, Chief Accounting Officer
Sold after exercise
1,809
$258.31
$467.29K
van der Vaart Sandra D
15 Sep 2021
EVP, Chief Legal Officer
Sold after exercise
4,500
$296.78
$1.34M
van der Vaart Sandra D
7 Jun 2021
EVP, Chief Legal Officer
Sold after exercise
4,500
$266.56
$1.20M
BELINGARD JEAN-LUC
3 May 2021
Director
Sold after exercise
2,600
$269.16
$699.80K
Wilkinson Peter J
18 Feb 2021
SVP, Chief Accounting Officer
Sold after exercise
2,317
$241.51
$559.59K
Williams R Sanders
8 Jul 2020
Director
Sold after exercise
1,300
$173.12
$225.06K
BELINGARD JEAN-LUC
19 Feb 2020
Director
Sold after exercise
26,479
$189.76
$5.02M
ANDERSON KERRII B
23 Sep 2019
Director
Sold after exercise
2,600
$171.85
$446.81K
Uthgenannt Lisa J
4 Sep 2019
Chief Human Resources Officer
Sold after exercise
2,466
$168.59
$415.74K
ANDERSON KERRII B
20 Jun 2019
Director
Sold after exercise
3,100
$170.00
$527.00K
MITTELSTAEDT ROBERT E JR
3 May 2019
Director
Sold after exercise
3,700
$166.30
$615.31K
BELINGARD JEAN-LUC
12 Feb 2019
Director
Sold after exercise
3,700
$146.06
$540.41K
ANDERSON KERRII B
5 Nov 2018
Director
Sold after exercise
3,700
$163.29
$604.16K
Dodson Edward T
6 Jun 2018
Principal Accounting Officer
Sold after exercise
13,000
$183.35
$2.38M
KING DAVID P
23 May 2018
President & CEO
Sold after exercise
5,400
$176.13
$951.09K
KING DAVID P
23 May 2018
President & CEO
Sold after exercise
44,566
$175.27
$7.81M
KING DAVID P
23 Apr 2018
President & CEO
Sold after exercise
21,200
$166.37
$3.53M
KING DAVID P
23 Apr 2018
President & CEO
Sold after exercise
28,767
$165.94
$4.77M
KING DAVID P
23 Mar 2018
President & CEO
Sold after exercise
1,700
$166.38
$282.84K
KING DAVID P
23 Mar 2018
President & CEO
Sold after exercise
10,313
$165.39
$1.71M
KING DAVID P
23 Mar 2018
President & CEO
Sold after exercise
36,265
$164.55
$5.97M
KING DAVID P
23 Mar 2018
President & CEO
Sold after exercise
1,689
$163.58
$276.29K
ANDERSON KERRII B
9 Feb 2018
Director
Sold after exercise
3,300
$166.10
$548.12K
KING DAVID P
6 Sep 2017
President & CEO
Sold after exercise
7,500
$157.34
$1.18M
KING DAVID P
6 Sep 2017
President & CEO
Sold after exercise
37,187
$156.77
$5.83M
KING DAVID P
5 Sep 2017
President & CEO
Sold after exercise
132,713
$157.06
$20.84M
EBERTS F SAMUEL III
25 Aug 2017
Chief Legal Officer, Secretary
Sold after exercise
31,500
$155.22
$4.89M
Williams R Sanders
11 Aug 2017
Director
Sold after exercise
11
$156.92
$1.73K
Williams R Sanders
11 Aug 2017
Director
Sold after exercise
8
$156.91
$1.26K
Williams R Sanders
11 Aug 2017
Director
Sold after exercise
2,881
$156.90
$452.02K
Williams R Sanders
11 Aug 2017
Director
Sold after exercise
200
$156.68
$31.34K
BELINGARD JEAN-LUC
9 May 2017
Director
Sold after exercise
992
$142.19
$141.05K
MITTELSTAEDT ROBERT E JR
24 Feb 2017
Director
Sold after exercise
367
$142.72
$52.38K
MITTELSTAEDT ROBERT E JR
24 Feb 2017
Director
Sold after exercise
100
$142.70
$14.27K
MITTELSTAEDT ROBERT E JR
24 Feb 2017
Director
Sold after exercise
2,000
$142.69
$285.38K
MITTELSTAEDT ROBERT E JR
24 Feb 2017
Director
Sold after exercise
2,633
$142.69
$375.69K
MITTELSTAEDT ROBERT E JR
24 Feb 2017
Director
Sold after exercise
200
$142.68
$28.54K
ANDERSON KERRII B
23 Feb 2017
Director
Sold after exercise
1,000
$140.00
$140.00K
ANDERSON KERRII B
23 Feb 2017
Director
Sold after exercise
992
$140.00
$138.88K
Show all 219 transactions →

What was left out

Form 4 filings counted 732
Amendments (4/A) skipped 2
Filings about a different issuer 1
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 35
Sales straight out of an exercise 61
Sales at will 114
Transactions with no price 0
Shares from compensation/vesting 2,552,387
Sales filed before the plan box existed 84
History held since 7 Sep 2016